Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.
Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.
Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer
Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.
Can Johnson & Johnson’s RIPTAC bet deliver the next wave of targeted oral cancer drugs?
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?
The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025 […]
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
Rubraca’s FDA approval before chemo in BRCA-mutated prostate cancer could reshape precision treatment. See what this changes for mCRPC strategy.